I certainly agree that if we do partner the royalty has a very...

I certainly agree that if we do partner the royalty has a very good chance of being higher than usual. Main point of interest being that it is not an indication that will require extensive advertising and boots on the ground in terms of sales reps in order to gain market penetration.

This is a very niche disease with very, very little treatment options available. It won't take much for news of an FDA approved drug that actually shows results to spread quickly to the specialist physicians and parent groups that are desperately waiting for a new treatment for their boys.

No idea why the market doesn't get it, but as we've seen with IMU recently the re-rate will come quickly when they do.